Humoral Response to the Pfizer BNT162b2 #Vaccine in Patients Undergoing Maintenance #Hemodialysis

Coronavirus disease 2019 (COVID-19) is associated with higher morbidity and mortality in patients on maintenance hemodialysis. Patients on dialysis tend to have a reduced immune response to infection or vaccination. We aimed to assess, for the first time to the best of our knowledge, the humoral response following vaccination with the BNT162b2 vaccine in patients on maintenance hemodialysis and the factors associated with it. Design, … Continue reading Humoral Response to the Pfizer BNT162b2 #Vaccine in Patients Undergoing Maintenance #Hemodialysis

Rate This

Appropriate Use of Short-Course #Antibiotics in Common #Infections: Best Practice Advice From the American College of Physicians

Antimicrobial overuse is a major health care issue that contributes to antibiotic resistance. Such overuse includes unnecessarily long durations of antibiotic therapy in patients with common bacterial infections, such as acute bronchitis with chronic obstructive pulmonary disease (COPD) exacerbation, community-acquired pneumonia (CAP), urinary tract infections (UTIs), and cellulitis. This article describes best practices for prescribing appropriate and short-duration antibiotic therapy for patients presenting with these … Continue reading Appropriate Use of Short-Course #Antibiotics in Common #Infections: Best Practice Advice From the American College of Physicians

Rate This

Risk for recurrent #cardiovascular disease events among patients with #diabetes and chronic kidney disease

Adults who have experienced multiple cardiovascular disease (CVD) events have a very high risk for additional events. Diabetes and chronic kidney disease (CKD) are each associated with an increased risk for recurrent CVD events following a myocardial infarction (MI). Methods We compared the risk for recurrent CVD events among US adults with health insurance who were hospitalized for an MI between 2014 and 2017 and … Continue reading Risk for recurrent #cardiovascular disease events among patients with #diabetes and chronic kidney disease

Rate This

#Renal Failure is Associated With Increased Mortality and Hospital Utilization in Patients Admitted With Nonalcoholic #Steatohepatitis

We aimed to investigate the mortality and hospital utilization outcomes of hospitalized nonalcoholic steatohepatitis (NASH) patients with and without kidney failure in a nationwide cohort.. ..The overall sample included 7,135,090 patients. Among 6855 patients admitted for NASH, 598 or 8.7% had comorbid kidney failure. After multivariate regression analysis, NASH patients with renal failure had increased in-hospital mortality [odds ratio=28.72, 95% confidence interval (CI): 8.99-91.73], length … Continue reading #Renal Failure is Associated With Increased Mortality and Hospital Utilization in Patients Admitted With Nonalcoholic #Steatohepatitis

Rate This

Diagnosis-wide analysis of #COVID-19 complications: an exposure-crossover study

Many studies reporting coronavirus disease 2019 (COVID-19) complications have involved case series or small cohorts that could not establish a causal association with COVID-19 or provide risk estimates in different care settings. We sought to study all possible complications of COVID-19 to confirm previously reported complications and to identify potential complications not yet known.. ..Among 70 288 patients with COVID-19, 69 of 1724 analyzed ICD-10-CM … Continue reading Diagnosis-wide analysis of #COVID-19 complications: an exposure-crossover study

Rate This

Comparison of #gabapentin and #doxepin in the management of #uremic pruritus: A randomized crossover clinical trial

Gabapentin and doxepin are well‐known treatments of uremic pruritus in hemodialysis patients but no head‐to‐head studies were conducted to date. The aim of this trial is to compare the efficacy and the tolerability of gabapentin and doxepin in the treatment of uremic pruritus in hemodialysis patients. A single‐blind crossover randomized trial was conducted that included hemodialysis patients with uremic pruritus. Patients were randomized to receive … Continue reading Comparison of #gabapentin and #doxepin in the management of #uremic pruritus: A randomized crossover clinical trial

Rate This

Risk Factor Control and #Cardiovascular Event Risk in People With Type 2 #Diabetes in Primary and Secondary Prevention Settings

To examine the association between the degree of risk factor control and cardiovascular disease (CVD) risk in type 2 diabetes and to assess if the presence of cardio-renal disease modifies these relationships. A retrospective cohort study using data from English practices from CPRD GOLD (Clinical Practice Research Datalink) and the SCI-Diabetes dataset (Scottish Care Information-Diabetes), with linkage to hospital and mortality data. We identified 101 749 … Continue reading Risk Factor Control and #Cardiovascular Event Risk in People With Type 2 #Diabetes in Primary and Secondary Prevention Settings

Rate This

The #Kidney Disease: Improving Global Outcomes (KDIGO) 2020 Clinical Practice Guideline for #Diabetes Management in Chronic Kidney Disease (CKD)

Here attached you may find the takeaways of the guidelines for patients and for clinicians. takeaways for patients: https://kdigo.org/wp-content/uploads/2018/03/Top-10-Takeaways-Patients.pdf takeaways for clinicians: https://kdigo.org/wp-content/uploads/2018/03/Top-10-Takeaways-Clinicians.pdf Continue reading The #Kidney Disease: Improving Global Outcomes (KDIGO) 2020 Clinical Practice Guideline for #Diabetes Management in Chronic Kidney Disease (CKD)

Rate This

Low High‐Sensitivity C‐ #Reactive Protein Level in Korean Patients With Chronic #Kidney Disease and Its Predictive Significance for Cardiovascular Events, Mortality, and Adverse Kidney Outcomes: Results From KNOW‐CKD

Inflammation levels are lower in East Asians than in Western people. We studied the association between high‐sensitivity hs‐CRP (C‐reactive protein) and adverse outcomes in Korean patients with chronic kidney disease. Methods and Results We included 2018 participants from the KNOW‐CKD (Korean Cohort Study for Outcome in Patients With Chronic Kidney Disease) between April 2011 and February 2016. The primary outcome was a composite of extended … Continue reading Low High‐Sensitivity C‐ #Reactive Protein Level in Korean Patients With Chronic #Kidney Disease and Its Predictive Significance for Cardiovascular Events, Mortality, and Adverse Kidney Outcomes: Results From KNOW‐CKD

Rate This

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, its long-term effects on kidney and cardiovascular outcomes are unknown. ..During a median follow-up of 2.6 years, a primary outcome event occurred in 504 of 2833 patients (17.8%) in the finerenone group and 600 of 2841 patients (21.1%) in the placebo … Continue reading Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Rate This

#Hypoalbuminemia is associated with increased risk of acute #kidney injury in hospitalized patients: A meta-analysis

Highlights • Each 1.0 g/dL of serum albumin decrement was associated with increased odds of AKI (OR 1.685; 95% CI, 1.302–2.179). • The risk factors for AKI in hypoalbuminemic patients include 1) age ≥ 70 years and 2) baseline serum albumin level > 3.2 g/dL. • The association between hypoalbuminemia and overall mortality from AKI remained inconclusive as there was potential publication bias. https://bit.ly/2HeU31v Continue reading #Hypoalbuminemia is associated with increased risk of acute #kidney injury in hospitalized patients: A meta-analysis

Rate This

#Dapagliflozin in Patients with Chronic #Kidney Disease

Patients with chronic kidney disease have a high risk of adverse kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes, is not known.. ..The independent data monitoring committee recommended stopping the trial because of efficacy. Over a median of 2.4 years, a primary outcome event occurred in 197 of 2152 participants (9.2%) in the … Continue reading #Dapagliflozin in Patients with Chronic #Kidney Disease

Rate This